Follow-up of fatty acid β-oxidation disorders in expanded newborn screening era
Fatty acid β-oxidation (FAO) disorders have a wide variety of symptoms, not usually evident between episodes of acute decompensations. Cardiac involvement is frequent, and severe ventricular arrhythmias are suspected of causing sudden death. Expanded newborn screening (ENS) for these disorders, hopefully, contribute to prevent potentially acute life-threatening events. In order to characterize acute decompensations observed in FAO-deficient cases identified by ENS, a retrospective analysis was performed, covering a period of 9 years. Demographic data, number/type of acute decompensations, treatment, and follow-up were considered. Eighty-three clinical charts, including 66 medium-chain acyl-CoA dehydrogenase deficiency (MCADD), 5 carnitine-uptake deficiency (CUD), 3 carnitine palmitoyltransferase I and II (CPT I/II) deficiency, 5 very long-chain acyl-CoA dehydrogenase deficiency (VLCADD), and 4 multiple acyl-CoA dehydrogenase deficiency (MADD) cases were reviewed. Nineteen patients had acute decompensations (1 CPT I, 1 CPT II, 3 MADD, 14 MCADD). Six patients developed symptoms previously to ENS diagnosis. Severe clinical manifestations included multiple organ failure, liver failure, heart failure, and sudden death. Long-chain FAO disorders had the highest number of decompensations per patient.
What is Known:
• Severe ventricular arrhythmias are suspected to cause unexpected death in FAO disorders.
• Neonatal screening intends to reduce the incidence of severe metabolic crisis and death.
What is New:
• Acute severe decompensations occurred in FAO disorders diagnosed through neonatal screening.
• Sudden deaths were not avoided by starting treatment precociously.
KeywordsFatty acid ß-oxidation disorders Acute decompensations Sudden death
Creatine kinase muscle and brain subunits
- CPT I
Carnitine palmitoyltransferase I
- CPT II
Carnitine palmitoyltransferase II
Dry blood spot
Duchenne muscular dystrophy
Expanded newborn screening
Fatty acid β-oxidation
Long-chain fatty acid oxidation disorders
Multiple acyl-CoA dehydrogenase deficiency
Medium-chain acyl-CoA dehydrogenase deficiency
Very long-chain acyl-CoA dehydrogenase deficiency
The planning, carrying out, and reporting of the work was done by Patrícia Janeiro with guidance from Isabel Tavares de Almeida. Rita Jotta had a major contribution in data collection. Ruben Ramos and Fátima Ventura contributed with biochemical and molecular studies. Laura Vilarinho provided neonatal screening data. Ana Gaspar provided clinical outcome data and contributed in the article review process.
Compliance with ethical statements
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors. For this type of study, formal consent is not required.
- 1.Tucci S, Herebian D, Sturm M, Seibt A, Spiekerkoetter U (2012) Tissue-specific strategies of the very-long chain acyl-CoA dehydrogenase-deficient (VLCAD −/−) mouse to compensate a defective fatty acid β-oxidation. PLoS One 7(1–9):e45429. https://doi.org/10.1371/journal.pone.0045429 CrossRefGoogle Scholar
- 2.Moczulski D, Majak I, Mamczur D (2009) An overview of β-oxidation disorders. Postepy Hig Med Dosw 63:266–277Google Scholar
- 4.Gélinas R, Thompson-Legault J, Bouchard B, Daneault C, Mansour A, Gillis MA, Charron G, Gavino V, Labarthe F, Des Rosiers C (2011) Prolonged QT interval and lipid alterations beyond b-oxidation in very long-chain acyl-CoA dehydrogenase null mouse hearts. Am J Physiol Heart Circ Physiol 301(3):H813–H823. https://doi.org/10.1152/ajpheart.01275.2010 CrossRefGoogle Scholar
- 20.Jank JM, Maier EM, Reiβ DD, Haslbeck M, Kemter KF, Truger MS, Sommerhoff CP, Ferdinandusse S, Wanders RJ, Gersting SW, Muntau AC (2014) The domain-specific and temperature-dependent protein misfolding phenotype of variant medium-chain acyl-CoA dehydrogenase. PLoS One 9(4):e93852. https://doi.org/10.1371/journal.pone.0093852 CrossRefGoogle Scholar
- 21.Bonito CA, Nunes J, Leandro J, Louro F, Leandro P, Ventura FV, Guedes RC (2016) Unvealing the pathogenic molecular mechanisms of the most common variant (pK329E) in medium-chain acyl-CoA dehydrogenase deficiency by in vitro and in silico approaches. Biochemistry 55(51):7086–7098. https://doi.org/10.1021/acs.biochem.6b00759. CrossRefGoogle Scholar
- 22.Nennstiel-Ratzel U, Arenz S, Maier EM, Knerr I, Baumkötter J, Röschinger W, Liebl B, Hadorn HB, Roscher AA, von Kries R (2005) Reduced incidence of severe metabolic crises or death in children with medium chain acyl –CoA dehydrogenase deficiency homozygous for c.985A>G identified by neonatal sreening. Mol Genet Metab 85:157–151. https://doi.org/10.1016/j.ymgme.2004.12.010 CrossRefGoogle Scholar
- 23.Bakermans AJ, Geraedts TR, van Weeghel M, Denis S, João Ferraz M, Aerts JM, Aten J, Nicolay K, Houten SM, Prompers JJ (2011) Fasting-induced myocardial lipid accumulation in long-chain acyl-CoA dehydrogenase knockout mice is accompanied by impaired left ventricular fuction. Circ Cardiovasc Imaging 4:558–565. https://doi.org/10.1161/CIRCIMAGING.111.963751 CrossRefGoogle Scholar
- 24.Lovera C, Porta F, Caciotti A, Catarzi S, Cassanello M, Caruso U, Gallina MR, Morrone A, Spada M (2012) Sudden unexpected infant death (SUDI) in a newborn due to medium chain acyl CoA dehydrogenase (MACD) deficiency with an unusual severe genotype. Ital J Pediatr 38(59):1–3. https://doi.org/10.1186/1824-7288-38-59 Google Scholar